Evidence map›Paper›PMID 31544000›Full record

ArticleBMJ global health2019

Early detection of chronic kidney disease in low-income and middle-income countries: development and validation of a point-of-care screening strategy for India.

Christina Bradshaw, Dimple Kondal, Maria E Montez-Rath, Jialin Han, Yuanchao Zheng, Roopa Shivashankar, Ruby Gupta, Nikhil Srinivasapura Venkateshmurthy, Prashant Jarhyan, Sailesh Mohan and 7 more

Open access · goldAbstract read
In one paragraph

Article in BMJ global health, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 2 countries.

Christina BradshawDivision of Nephrology, Stanford University School of Medicine, Stanford, California, USA cbradsha@stanford.edu.ORCID http://orcid.org/0000-0002-5820-4781
Dimple KondalPublic Health Foundation of India, New Delhi, Delhi, India.
Maria E Montez-RathDivision of Nephrology, Stanford University School of Medicine, Stanford, California, USA.
Jialin HanDivision of Nephrology, Stanford University School of Medicine, Stanford, California, USA.
Yuanchao ZhengDivision of Nephrology, Stanford University School of Medicine, Stanford, California, USA.
Roopa ShivashankarCentre for Chronic Disease Control, Gurgaon, Haryana, India.
Ruby GuptaPublic Health Foundation of India, New Delhi, Delhi, India.
Nikhil Srinivasapura VenkateshmurthyPublic Health Foundation of India, New Delhi, Delhi, India.
Prashant JarhyanPublic Health Foundation of India, New Delhi, Delhi, India.
Sailesh MohanPublic Health Foundation of India, New Delhi, Delhi, India.
Viswanathan MohanDepartment of Diabetology, Madras Diabetes Research Foundation, Chennai, Tamil Nadu, India.
Mohammed K AliDepartment of Global Health, Emory University School of Public Health, Atlanta, Georgia, USA.
Shivani PatelDepartment of Global Health, Emory University School of Public Health, Atlanta, Georgia, USA.
K M Venkat NarayanDepartment of Global Health, Emory University School of Public Health, Atlanta, Georgia, USA.
Nikhil TandonDepartment of Endocrinology and Metabolism, All India Institute of Medical Sciences, New Delhi, Delhi, India.
Dorairaj PrabhakaranPublic Health Foundation of India, New Delhi, Delhi, India.
Shuchi AnandDivision of Nephrology, Stanford University School of Medicine, Stanford, California, USA.
Stanford University · USPublic Health Foundation of India · INCentre for Chronic Disease Control · INEmory University · USAll India Institute of Medical Sciences · INMadras Diabetes Research Foundation · IN

Funding

Research Mentoring and Building Capacity of underrepresented Minority Research Scientists in India.D43TW010540 · FIC · YALE UNIVERSITY · PI MICHELE BARRY, Eva Harris · 2017 to 2026
$15.5M
Global Health Fellows and Scholars Research TrainingR25TW009338 · FIC · UNIVERSITY OF CALIFORNIA BERKELEY · PI BARRY, MICHELE, KO, ALBERT ICKSANG · 2012 to 2016
$5.2M
TRAINING PROGRAM IN ACADEMIC NEPHROLOGYT32DK007357 · NIDDK · STANFORD UNIVERSITY · PI CHERTOW, GLENN MATTHEW · 1986 to 2022
$4.8M
Mentoring Patient-Oriented Clinical Investigators in NephrologyK24DK085446 · NIDDK · STANFORD UNIVERSITY · PI CHERTOW, GLENN MATTHEW · 2010 to 2022
$1.4M
Epidemiology and management of chronic kidney disease in South AsiansK23DK101826 · NIDDK · STANFORD UNIVERSITY · PI ANAND, SHUCHI · 2014 to 2018
$919k
FIC NIH HHS D43 TW010540FIC NIH HHS R25 TW009338NHLBI NIH HHS HHSN268200900026CNIDDK NIH HHS K23 DK101826NIDDK NIH HHS K24 DK085446NIDDK NIH HHS T32 DK007357
6 · The paper itself

Abstract

introductionAlthough deaths due to chronic kidney disease (CKD) have doubled over the past two decades, few data exist to inform screening strategies for early detection of CKD in low-income and middle-income countries.

methodsUsing data from three population-based surveys in India, we developed a prediction model to identify a target population that could benefit from further CKD testing, after an initial screening implemented during home health visits. Using data from one urban survey (n=8698), we applied stepwise logistic regression to test three models: one comprised of demographics, self-reported medical history, anthropometry and point-of-care (urine dipstick or capillary glucose) tests; one with demographics and self-reported medical history and one with anthropometry and point-of-care tests. The 'gold-standard' definition of CKD was an estimated glomerular filtration rate <60 mL/min/1.73 m

resultsA model with age, sex, waist circumference, body mass index and urine dipstick had a c-statistic of 0.76 (95% CI 0.75 to 0.78) for predicting need for further CKD testing, with external validation c-statistics of 0.74 and 0.70 in the urban and rural cohorts, respectively. At a probability cut-point of 0.09, sensitivity was 71% (95% CI 68% to 74%) and specificity was 70% (95% CI 69% to 71%). The model captured 71% of persons with CKD and 90% of persons at highest risk of complications from untreated CKD (ie, CKD stage 3A2 and above).

conclusionA point-of-care CKD screening strategy using three simple measures can accurately identify high-risk persons who require confirmatory kidney function testing.

Indexed as

community-based surveyepidemiologyscreening

Identifiers

PMID31544000
PMCPMC6730594
OpenAlexW2971387833

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.